MCXZ likely acts in DM by affecting PIK3R1, TNF, PRKACA, and other targets associated with insulin resistance and inflammation through the actions of various chemical components, including genistein, levodopa, and daidzein, which regulate multiple pathways, such as Type II diabetes mellitus, VEGF signaling pathway, Toll-like receptor signaling pathway, and Calcium signaling pathway. Here, PRKACA is linked to diabetes mellitus.